Viewing entries by
Rob Cohen

1 Comment

Finding the Upside: How Great Leaders Invest in Times of Uncertainty

n our latest perspective, Chrysalis looks at how best-in-class companies took action during the recession of '09-'11. The most successful companies acted decisively in the face of the downturn, engaging in everything from acquisitions to alliances to deep investments in strategically important assets. We provide examples and dissect three classes of activities: the acquisition of previously unavailable assets, doubling down on existing business hypotheses, and capturing scale by investing in strategically adjacent businesses. We hope you enjoy the read.

1 Comment

5 Questions With: Robert Green, MD, MPH Professor of Medicine (Genetics), Harvard Medical School

Continuing Chrysalis' "5 Questions" series, we reached out to one of the preeminent experts on the clinical use of whole genome sequencing. Robert C. Green, MD, MPH is a medical geneticist and physician-scientist who directs the G2P Research Program in translational genomics and health outcomes in the Division of Genetics at Brigham and Women’s Hospital, the Broad Institute and Harvard Medical School. Dr. Green sees patients and conducts empirical research on the medical, behavioral and economic outcomes associated with the implementation of genomic medicine.

1 Comment

5 Questions With: Erica Ramos

As part of our blog, Chrysalis Biomedical Advisors will be sharing a series of “5 Questions With...”. These are brief interviews with thought leaders in the healthcare and biotechnology space. We hope you enjoy them. Interested in nominating an individual and / or posing questions? Please contact rob@chrysalisbiomed.com or comment.

1 Comment